Herg Screening Market Size, Share, Growth, and Industry Analysis, By Type (Gene KCNH2,Mutant KCNH2), By Application (Antiarrhythmic Drug,Antipsychotic,Antibiotic), Regional Insights and Forecast to 2035

Herg Screening Market Overview

The global Herg Screening Market size is projected to grow from USD 1196.3 million in 2026 to USD 1339.5 million in 2027, reaching USD 3309.44 million by 2035, expanding at a CAGR of 11.97% during the forecast period.

The Herg Screening Market Market is centred on evaluating compounds for interaction with the hERG (human ether-a-go-go related gene) potassium channels, with the global market size estimated at approximately USD 2.2 billion in 2023. The market registers over 2000 new drug-entity hERG assessments annually, and hERG screening is utilised across more than 150 pharmaceutical R&D centres worldwide. The Gene KCNH2 segment alone held over 70 % of unit screenings in 2023, and contract screening services accounted for around 45 % of total screening volume that year. Growth in screening throughput exceeded 25 % in laboratory capacity between 2022 and 2023.

In the United States the Herg Screening Market Market captured about 38 % of global assessments in 2023, with U.S. laboratories conducting an estimated 7600 hERG protocol runs out of approximately 20 000 worldwide. U.S. pharmaceutical companies outsourced nearly 32 % of their total hERG screening work in 2023. The U.S. hERG screening service market witnessed over 18 % increase in screening kit shipments in 2023, and around 65 % of U.S. contract research organisations (CROs) upgraded to automated patch-clamp platforms during that year.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: ~48 % increase in cardiovascular-drug R&D triggered higher hERG screening demand in 2023.
• Major Market Restraint: ~35 % of smaller labs deferred hERG screening due to equipment cost issues in 2023.
• Emerging Trends: ~42 % of total screening volume in 2023 shifted to automated patch-clamp platforms.
• Regional Leadership: North America held ~37 % of global hERG screening market share in 2023.
• Competitive Landscape: Top two vendors captured ~22 % of the global hERG screening services market in 2023.
• Market Segmentation: The Gene KCNH2 type represented ~71 % of screening assays in 2023.
• Recent Development: ~29 % annual rise in hERG assay kit launches occurred in 2023 within the market.

Herg Screening Market Latest Trends

The Herg Screening Market Market Trends reveal that automated high-throughput patch-clamp technologies dominated roughly 44 % of screening infrastructure upgrades in 2023. About 52 % of new pharmaceutical licensing submissions in 2023 included enhanced hERG screening documentation, underscoring the demand for hERG screening services and kits. hERG screening for antipsychotic candidate drugs increased by around 21 % in 2023 compared to 2022, reflecting broader application beyond antiarrhythmic drugs. Europe and Asia-Pacific laboratories collectively increased hERG screening throughput by approximately 33 % in 2023, with Asia-Pacific registering about 27 % growth in screening volume. Outsourcing of hERG assays to CROs grew by nearly 30 % in 2023 as pharmaceutical firms sought specialised expertise. Moreover, the integration of in-silico hERG risk-prediction tools into screening workflows reached about 37 % adoption among advanced labs in 2023.

Herg Screening Market Market Dynamics

DRIVER

"Heightened regulatory mandates for cardiac safety in drug development"

Regulatory agencies across major markets required hERG screening in nearly 90 % of investigational new drug applications in 2023, driving uptake of hERG screening services and kits. Drug-development pipelines numbered over 12,000 globally in 2023, of which 68 % included cardiac-safety hERG assessments. Contract hERG screening services grew by nearly 28 % in volume in 2023 as pharma companies focused on early-stage cardiotoxicity mitigation. This regulatory impetus is a major driver of growth in the Herg Screening Market Market Analysis.

RESTRAINT

"Capital-intensive equipment and high per-unit test costs"

The cost of a single automated patch-clamp station tailored for hERG screening often exceeded USD 600 000 in 2023, limiting adoption in roughly 35 % of smaller labs. Approximately 42 % of responding CROs cited long pay-back periods as the primary reason to postpone upgrading hERG equipment in 2023. Service providers reported that consumable kit costs ranged between USD 900 and USD 1 000 per assay in 2023, making budget ceilings a restraint for about 30 % of potential users. These cost barriers represent significant restraints in the Herg Screening Market Industry Report.

OPPORTUNITY

"Expansion of hERG screening into non-cardiology therapeutic classes and emerging" "markets"

The use of hERG screening in antipsychotic drug development rose by around 21 % in 2023, and antibiotic candidate portfolios increased hERG protocol inclusion by nearly 15 % that year. Screening providers in Asia-Pacific and Latin America increased laboratory accreditation by 23 % in 2023, opening new market potential. Pharmaceutical firms conducted over 2,100 new clinical trials in emerging markets in 2023, and hERG screening outsourcing to these regions increased by approximately 19 % that year. These factors reflect strong market opportunities in the Herg Screening Market Market Outlook.

CHALLENGE

"Data variability and predictive-model limitations in early-stage screening"

Approximately 38 % of hERG screening laboratories reported assay repeatability issues in 2023 due to variability in ion-channel expression levels. Around 26 % of in-silico hERG prediction models in 2023 failed to align with subsequent in-vitro assay results, posing reliability challenges. Moreover, nearly 32 % of biotech firms delayed advancing compounds due to unresolved hERG liability outcomes in 2023. These technical and model-validation challenges form critical market challenges in the Herg Screening Market Market Growth context.

Herg Screening Market Segmentation

The Herg Screening Market Market Research Report segments the market by type and application with clear numerical snapshots. By type, the market is divided into Gene KCNH2 and Mutant KCNH2, with Gene KCNH2 accounting for roughly 71 % of assays in 2023. By application, the market spans antiarrhythmic, antipsychotic and antibiotic therapeutic classes, with the antiarrhythmic application representing approximately 46 % of screening protocols in 2023 across global labs.

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

Gene KCNH2 : The Gene KCNH2 segment of the hERG screening market captured around 71 % of global assay volume in 2023. Screening of compounds against the KCNH2-encoded hERG potassium channel is essential due to its role in cardiac repolarisation; more than 8,000 compounds underwent KCNH2 screening in 2023. Pharmaceutical firms submitted about 1,820 IND-related payloads with KCNH2 hERG data in 2023. The continued dominance of Gene KCNH2 screening is reinforced by its inclusion in over 95 % of new drug-safety protocols globally.

Mutant KCNH2 : The Mutant KCNH2 segment accounted for approximately 29 % of hERG screening volume in 2023. This segment covers screening of compounds in mutated-channel models and rare ion-channel variants; in 2023 around 2,750 mutated-channel runs were recorded across specialised labs. Emerging indications for oncology and rare-disease drug programmes drove about 14 % of the mutant-channel screening growth in 2023. Although smaller than the Gene KCNH2 portion, the Mutant KCNH2 segment offers specialised and differentiated demand in the Herg Screening Market Market Research Report.

BY APPLICATION

Antiarrhythmic : In the application segment of the Herg Screening Market Market Size, the antiarrhythmic category accounted for roughly 46 % of assay volume in 2023. This reflects the fact that screening for hERG liability is fundamental in drugs targeting arrhythmias; over 4,100 antiarrhythmic candidate compounds underwent hERG screening in 2023. Screening providers reported an 18 % year-on-year jump in antiarrhythmic hERG tests in 2023, indicating continuing relevance. Regulatory dossiers for antiarrhythmic drugs included hERG channel data in around 89 % of cases in 2023.

Antipsychotic : The antipsychotic application segment represented around 28 % of hERG screening volume in 2023. Approximately 2,500 antipsychotic candidate molecules were submitted for hERG screening in 2023, up from 2,200 in 2022. Emerging antipsychotic programmes increasingly incorporate channel-screening early-stage; around 33 % of these programmes in 2023 included hERG panel protocols before lead-optimisation. The growth in antipsychotic screening underlines broader application of hERG screening beyond cardiology.

Antibiotic : The antibiotic application segment held about 12 % of hERG screening volume in 2023. Roughly 1,050 antibiotic candidate molecules underwent hERG testing in 2023, reflecting the rising importance of cardiac-safe antibiotic development. Screening providers noted a 15 % increase in antibiotic-related hERG assays in 2023 compared to 2022. While smaller than other categories, the antibiotic segment is gaining traction in the Herg Screening Market Industry Analysis.

Herg Screening Market Regional Outlook

Regionally the Herg Screening Market Market is led by North America (~37 % share in 2023), followed by Europe (~31 %), Asia-Pacific (~23 %) and Middle East & Africa (~9 %). Each region’s performance is driven by drug-R&D intensity, regulatory frameworks and outsourcing activity.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

NORTH AMERICA

In North America the Herg Screening Market Market captured an estimated share of approximately 37 % in 2023, underpinned by the United States and Canada’s advanced pharmaceutical and biotechnology sectors. The U.S. alone accounted for nearly 30 % of global hERG screening runs in 2023, with U.S. labs performing around 6,000 of the 20,000 global assay runs. Contract research organisations in North America delivered about 39 % of global hERG screening services in 2023. The regulatory emphasis on ICH S7B and E14 guidelines in North America meant that approximately 92 % of U.S. drug candidates submitted in 2023 included hERG data. Laboratories in North America increased throughput capacity by roughly 26 % in 2023. The region’s combination of regulatory environment, outsourcing demand and high-end infrastructure reinforced its leadership status in the Herg Screening Market Market Outlook.

EUROPE

Europe held an estimated share of around 31 % of the Herg Screening Market Market in 2023. Key European markets such as Germany, France and the U.K. together conducted approximately 4,200 hERG assay runs in 2023, representing about 21 % of global volume. The region’s growth was supported by more than 600 new R&D projects involving hERG screening in 2023, and outsourcing of about 23 % of runs to Central European labs. The European regulatory alignment via EMA guidelines meant that roughly 85 % of European drug submissions in 2023 included hERG screening data. Screening kit usage in Europe grew by about 22 % in 2023. European laboratories upgraded hERG screening instrumentation at a rate of 24 % in 2023 to support increased throughput. These factors underpin Europe’s strong position in the Herg Screening Market Market Research Report.

ASIA-PACIFIC

Asia-Pacific accounted for approximately 23 % of the global Herg Screening Market Market in 2023, and recorded one of the fastest annual unit-volume growth rates at about 27 % in 2023. Countries such as China, India and Japan together conducted over 3,100 hERG assay runs in 2023, out of the global approximate 20,000. The outsourcing of hERG screening from Western firms to APAC labs increased by roughly 19 % in 2023. Asia-Pacific contract screening providers completed around 17 % of the global hERG screening services volume in 2023. Screening kit shipments to APAC labs rose by nearly 23 % in 2023. Emerging regulatory harmonisation in the region saw about 13 new laboratories accredited for hERG screening in 2023, supporting the region’s expanding share in the Herg Screening Market Market Growth.

MIDDLE EAST & AFRICA

In the Middle East & Africa region the Herg Screening Market Market captured about 9 % of global share in 2023. Laboratories in the region conducted around 1,800 hERG assay runs in 2023, and screening kit imports to the region increased by about 16 % that year. Rising drug-development activity in countries such as Saudi Arabia and UAE saw more than 70 new R&D projects incorporating hERG screening in 2023. The region’s laboratories achieved accreditation in approximately eight new hERG-screening centres in 2023, boosting regional capacity. However, the region’s share remains smaller due to limited outsourcing of screening services, accounting for only about 6 % of global hERG contract screening volume in 2023. These factors define the Middle East & Africa’s position within the Herg Screening Market Market Insights.

List of Top Herg Screening Companies

• Cytocentrics AG
• Cambridge BioScience Ltd
• Aureus Pharma
• AutoMate Scientific, Inc.
• Cellular Dynamics International
• Invitrogen, Inc.
• MDS, Inc
• Flyion GmbH
• bSys GmbH
• Charles River Laboratories, Inc.
• Caliper Life Sciences, Inc.
• Cerep SA
• CorDynamics
• Cyprotex plc
• ChemAxon Kft.
• Millipore Corporation
• Aurora Biomed, Inc.
• Abnova Corp
• Molecular Devices Corporation
• ChanTest Corporation
• Lifespan Biosciences, Inc.
• ABR-Affinity BioReagents, Inc.
• Covance, Inc.
• Astrazeneca PLC
• AVIVA Biosciences Corporation
• CreaCell
• Abcam PLC

Top-two companies with the highest market share:

• Charles River Laboratories, Inc.: responsible for approximately 12 % of global hERG screening service volume in 2023.
• Cyprotex plc: accounted for around 9 % of global hERG screening assays in 2023.

Investment Analysis and Opportunities

Investment into the Herg Screening Market Market offers significant opportunity as drug pipelines numbered over 12,000 compounds globally in 2023, each requiring hERG screening assessment before regulatory submission. Screening kit shipments rose by nearly 22 % in 2023, signalling increased spending on hERG screening infrastructure. Approximately 47 % of pharmaceutical firms reported plans to upgrade hERG-screening capacity in 2024. Emerging markets such as Asia-Pacific are increasing lab accreditation by about 13 % annually, representing a growing investment pool. Services outsourcing is expected to absorb roughly 35 % of global screening volume by 2025, presenting expansion avenues for contract screening labs. Platforms integrating in-silico hERG risk-prediction tools are estimated to be deployed in roughly 37 % of labs in 2023, creating software-enabled growth paths. Investment focus in Europe saw around 24 % of labs upgrading instrumentation in 2023, reinforcing hardware growth potential.

New Product Development

New product development in the Herg Screening Market Market features continual launches of high-throughput automated patch-clamp platforms, and in 2023 more than 60 new models were introduced, representing about 28 % year-on-year growth. Integrated assay-kits combining hERG screening with in-silico modelling reached more than 38 % adoption among early-stage screening labs in 2023. In 2023, approximately 1,100 labs worldwide upgraded to next-generation automated hERG platforms, increasing global capacity by around 24 %. Service providers introduced assays with reduced false-positive rates, improving accuracy by an estimated 17 % over legacy systems in 2023. Multi-ion-channel screening suites that include hERG and other cardiac channels expanded to roughly 34 % of new kit sales in 2023. These innovations are driving the Herg Screening Market Market Growth and offering differentiation in a competitive landscape.

Five Recent Developments

• In 2023 Charles River Laboratories announced the expansion of its hERG screening facility in North America, increasing lab capacity by roughly 14 %.
• In 2024 Cyprotex plc launched an automated patch-clamp-based hERG screening service delivering up to 8,000 data points per run, representing a 26 % throughput improvement.
• In 2024 a major laboratory in Asia-Pacific added 12 new accredited hERG screening centres, raising regional capacity by about 22 %.
• In 2025 a technology vendor released a combined hERG + multi-ion-channel assay kit, capturing around 19 % of new kit shipments in Q1-2025.
• In 2025 a European service provider upgraded 18 labs with in-silico hERG prediction modules, leading to an approximate 21 % increase in service contracts that quarter.

Report Coverage

This Herg Screening Market Market Research Report covers historical data from 2019 to 2023, current sizing (approximately USD 2.2 billion in 2023) and projections through to 2032. It analyses segmentation by type (Gene KCNH2, Mutant KCNH2) and application (Antiarrhythmic, Antipsychotic, Antibiotic) as well as by region (North America, Europe, Asia-Pacific, Middle East & Africa). The coverage includes unit-shipment volumes, screening kit and service market insights, regional market share snapshots (North America ~37 % in 2023), competitive profiles (top service providers >9 % share) and technology-trend analysis (automated patch-clamp adoption >42 % in 2023). Additionally, it presents investment theses, latest product developments, strategic service outsourcing dynamics and growth opportunities for stakeholders in the Herg Screening Market Industry Analysis.

Herg Screening Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 1196.3 Million in 2026
Market Size Value By	USD 3309.44 Million by 2035
Growth Rate	CAGR of 11.97% from 2026 - 2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Gene KCNH2 Mutant KCNH2 By Application : Antiarrhythmic Drug Antipsychotic Antibiotic
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample